Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523238 | 0.82 | SLC6A15 (0.41) | SLC6A15MRGPRX4KDM4CKDM1A | |
| SCHEMBL20523241 | 0.82 | SLC6A15 (0.41) | SLC6A15MRGPRX4KDM4CKDM1A | |
| SCHEMBL22254440 | 0.79 | — | — | |
| SCHEMBL30073899 | 0.79 | — | — | |
| SCHEMBL23386593 | 0.78 | BCL2L11 (0.39) | SLC6A15MRGPRX4KDM4CBCL2L11MCL1 | |
| SCHEMBL20528069 | 0.70 | MCL1 (0.51) | BCL2L11MCL1 | |
| SCHEMBL20528068 | 0.70 | MCL1 (0.51) | BCL2L11MCL1 | |
| SCHEMBL22254449 | 0.69 | PARP1 (0.32) | MRGPRX4 | |
| SCHEMBL23386591 | 0.69 | SLC6A15 (0.40) | SLC6A15MRGPRX4KDM4CCNR2KDM1A | |
| SCHEMBL22254553 | 0.68 | MRGPRX4 (0.32) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | SLC6A15 4549/4885MRGPRX4 3931/4885KDM4C 3542/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | SLC6A15 4546/4885MRGPRX4 3912/4885KDM4C 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.